Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Raltegravir potassium
Drug ID BADD_D01906
Description Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status Prescription
ATC Code J05AJ01
DrugBank ID DB06817
KEGG ID D07133
MeSH ID D000068898
PubChem ID 23668479
TTD Drug ID D0I1FQ
NDC Product Code 65015-841; 67651-0276; 50473-0001; 67317-0031; 70600-028; 67317-0001; 67651-0274; 62331-055; 65977-0129; 67651-0275
Synonyms Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress
Chemical Information
Molecular Formula C20H20FKN6O5
CAS Registry Number 871038-72-1
SMILES CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Abnormal behaviour19.01.01.001--Not Available
Anal cancer16.13.05.001; 07.21.05.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Polyp16.02.02.005; 08.01.06.010--Not Available
Blood disorder01.05.01.004--Not Available
Autoimmune disorder10.04.04.003--
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.001--
Renal impairment20.01.03.010--Not Available
Lipohypertrophy23.07.01.005; 14.08.04.009--
Poor quality sleep19.02.05.005; 17.15.04.002--Not Available
Chronic kidney disease20.01.03.017--
Waist circumference increased13.15.01.033--Not Available
Suicidal behaviour19.12.01.006--Not Available
Anorectal discomfort07.03.03.003--Not Available
Fasting26.01.02.001--Not Available
Hepatic cancer16.07.02.004; 09.04.02.008--Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.010--Not Available
The 9th Page    First    Pre   9    Total 9 Pages